Phase I Study of ARN-509, a Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate Cancer

PURPOSE: ARN-509 is a novel androgen receptor (AR) antagonist for the treatment of castration-resistant prostate cancer (CRPC). ARN-509 inhibits AR nuclear translocation and AR binding to androgen response elements and, unlike bicalutamide, does not exhibit agonist properties in the context of AR ov...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Rathkopf, Dana E., Morris, Michael J., Fox, Josef J., Danila, Daniel C., Slovin, Susan F., Hager, Jeffrey H., Rix, Peter J., Chow Maneval, Edna, Chen, Isan, Gönen, Mithat, Fleisher, Martin, Larson, Steven M., Sawyers, Charles L., Scher, Howard I.
Format: Artigo
Sprog:Inglês
Udgivet: American Society of Clinical Oncology 2013
Fag:
Original Reports
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3782148/
https://ncbi.nlm.nih.gov/pubmed/24002508
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2013.50.1684
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker